Dopamine Dysregulation Syndrome in Parkinson’s Disease

This case study examines how patients with Parkinson's disease (PD) may develop dopamine dysregulation syndrome (DDS), a condition characterized by the misuse of dopamine replacement therapy through excessive self-directed dosing beyond what is necessary to control motor symptoms. While carbidopa/levodopa remains the mainstay therapy for many adults with PD, some patients may choose Mucuna pruriens, a complementary medicine containing levodopa, to manage their motor symptoms. This case describes a patient with PD who presents with DDS following co-administration of self-directed Mucuna pruriens alongside extended-release (ER) and immediate-release (IR) carbidopa/levodopa. Recognizing the presentation and risk factors of DDS is crucial, as is educating and monitoring patients with PD to prevent misuse of both their prescribed dopamine replacement therapy and Mucuna pruriens supplements.

Authors

Institutions

Publication Details

Journal
The Senior Care Pharmacist
Published
2025-11-01
DOI
https://doi.org/10.4140/tcp.n.2025.450
Citations
2
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dopamine Dysregulation Syndrome in Parkinson’s Disease

Linda H. Poon, Audrey J. Lee
2 citations
The Senior Care Pharmacist
Parkinson's Disease Mechanisms and Treatments
2.78
article

Dopamine Dysregulation Syndrome in Parkinson’s Disease

Linda H. Poon, Audrey J. Lee
article en
2 citations

Abstract

This case study examines how patients with Parkinson's disease (PD) may develop dopamine dysregulation syndrome (DDS), a condition characterized by the misuse of dopamine replacement therapy through excessive self-directed dosing beyond what is necessary to control motor symptoms. While carbidopa/levodopa remains the mainstay therapy for many adults with PD, some patients may choose Mucuna pruriens, a complementary medicine containing levodopa, to manage their motor symptoms. This case describes a patient with PD who presents with DDS following co-administration of self-directed Mucuna pruriens alongside extended-release (ER) and immediate-release (IR) carbidopa/levodopa. Recognizing the presentation and risk factors of DDS is crucial, as is educating and monitoring patients with PD to prevent misuse of both their prescribed dopamine replacement therapy and Mucuna pruriens supplements.

The Senior Care PharmacistVol. 40(11)
University of the Pacific (US)
Openalex Percentile: Top 8%
Parkinson's Disease Mechanisms and Treatments
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Dopamine Dysregulation Syndrome in Parkinson’s Disease — Linda H. Poon, Audrey J. Lee · The Senior Care Pharmacist (2025) | TGRS Research Map | TGRS